Cargando…
Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume
BACKGROUND: Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score that predicts anti-PD-(L)1 response in patients...
Autores principales: | Belkouchi, Younes, Nebot-Bral, Laetitia, Lawrance, Littisha, Kind, Michele, David, Clémence, Ammari, Samy, Cournède, Paul-Henry, Talbot, Hugues, Vuagnat, Perrine, Smolenschi, Cristina, Kannouche, Patricia L., Chaput, Nathalie, Lassau, Nathalie, Hollebecque, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641225/ https://www.ncbi.nlm.nih.gov/pubmed/36387101 http://dx.doi.org/10.3389/fonc.2022.982790 |
Ejemplares similares
-
Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker
por: Naccache, Raphael, et al.
Publicado: (2022) -
Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion
por: Li, Yingping, et al.
Publicado: (2022) -
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022) -
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
por: Decazes, Pierre, et al.
Publicado: (2023) -
Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs
por: Decazes, Pierre, et al.
Publicado: (2023)